ARTICLE | Company News
Asklepios, Benitec deal
May 25, 2015 7:00 AM UTC
Asklepios granted Benitec rights to advanced recombinant adeno-associated virus (AAV) gene therapy technologies. Benitec has access to the technologies for its Phase I/II trial of TT-034 to treat HCV...